Xifaxan does not have a biosimilar risk because rifaximin is a small-molecule drug. Its principal competitive threat is an abbreviated new drug application, or ANDA, for generic rifaximin tablets. How much does Xifaxan generate in sales? Bausch reports Xifaxan as a major contributor to Salix revenue. Annual Sales of Xifaxan reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. How many physicians were reached by Xifaxan through reportable promotional activity in 2020 and how does this compare to its peer set in the Hepatic Encephalopathy, Irritable Bowel Syndrome, and Traveler's Diarrhea markets? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity? How does … NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … • Reported Revenue of XIFAXAN® (rifaximin) Increased by 23% Compared to the First Quarter of 2019 • Lowered 2020 Full-Year Revenue and Adjusted EBITDA (Non-GAAP) Guidance Ranges Primarily Due to Impact of COVID-19 Pandemic Annual Sales of Xifaxan, Rifacol, Fatroximin, Rifaximin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Increased total Company reported revenue by 5% compared to the full year of 2020 Reported revenue for XIFAXAN® (rifaximin) grew by 11% during the full year of 2021 compared to the full year of 2020 Mechanism xifaxan sales 2020 of action is unknown and does not imply clinical efficacy XIFAXAN is the only FDA-approved, nonsystemic IBS-D treatment that alters the microbiome 1: Less than 0. Salix Will Maintain Market Exclusivity for XIFAXAN® (rifaximin) 200 mg and 550 mg Tablets Until 20281 LAVAL, QC, Sept. 22, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its gastroenterology business, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in the world committed to the … Thanks to the team at EvaluatePharma and its Vantage 2020 Preview report, we here at FiercePharma have compiled a list of top 10 drugs by estimated sales increase in 2020–a group comprising … Xifaxan® (rifaximin) Case Name: Norwich Pharms., Inc. v. Kennedy Jr., Civ. No. 25-91, 2025 WL 1148463 (D.D.C. Apr. 18, 2025) (Howell, J.) Drug Product and Patent (s)-in-Suit: Xifaxan® (rifaximin) Nature of the Case and Issue (s) Presented: Salix holds NDAs for 200mg and 550mg Xifaxan. The 550mg strength product was approved to treat irritable bowel syndrome with diarrhea ("IBS-D indication … BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. Bausch has separately agreed to allow Xifaxan generics from Teva Pharmaceuticals, Sun Pharmaceuticals and Sandoz starting in 2028 after settling related patent disputes. Salix in 2020 sued New York state-based Norwich over its proposed generic of Xifaxan. XIFAXAN tablets for oral administration are film-coated and contain 200 mg or 550 mg of rifaximin. Inactive ingredients: Each 200 mg tablet contains colloidal silicon dioxide, disodium edetate, glycerol palmitostearate, hypromellose, microcrystalline cellulose, propylene glycol, red iron oxide, sodium starch glycolate, talc, and titanium dioxide. Each 550 mg tablet contains colloidal silicon … Rifaximin Market Insights Global Rifaximin Market size reached USD 73 million in 2025 and is forecasted to rise from USD 78 million in 2026 to USD 110 million by 2034, exhibiting a compound annual growth rate of approximately 5.3% over the period. Reflecting recent therapeutic expansions and heightened stewardship initiatives, the CAGR has been refined upward to capture the stronger momentum … Bausch Health Companies Inc.'s BHC reported second-quarter adjusted earnings per share of 89 cents, on par with the Zacks Consensus Estimate. The reported figure increased from 81 cents in the … The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan. Relistor and Trulance revenues were up 9% each. Xifaxan 550 mg tablets are indicated for the reduction in the risk of overt hepatic encephalopathy recurrence and the treatment of IBS-D in adults. Our Take on BHC's Q3 Results Bausch's third-quarter results were encouraging, with sales and earnings beating estimates. The increase in guidance was another positive. The Salix business maintained its momentum on the back of Xifaxan, which witnessed strong growth in underlying demand. Cosmo Pharmaceuticals' antibiotic Aemcolo poses a serious threat to Bausch Health's top-selling antibiotic Xifaxan. (Bausch Health) Bausch Health has yet to fully recover from its tainted past … The global Rifaximin market size is expected to reach $ 105 million by 2031, rising at a market growth of 4.5% CAGR during the forecast period (2025-2031). While Bausch didn't break out specific sales figures for Xifaxan, it did note that the med's revenues jumped 11% for the full year compared to 2020. BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales. Sales for Xifaxan in the IBS Market GlobalData estimates that the Xifaxan off-label sales for IBS in 2013 were approximately $138.4m across the seven major markets (7MM) covered in this report. By the end of the forecast period in 2023, Xifaxan sales will increase approximately to $222.2m, at a Compound Annual Growth Rate (CAGR) of 4.84%. – Bausch Health reported $2.68B Q3 revenue (7% YoY growth) driven by Solta Medical's 25% growth and Salix's 12% growth via AI-driven insights. – Xifaxan revenue outpaced prescription growth due to one-time pricing adjustments, with CMS pricing expected Nov 30 to impact 30% of Medicare Part D volume. – DURECT acquisition boosted R&D pipeline in hepatology, while exiting 340B/Medicaid aims to … Sales growth was driven by Xifaxan® and Relistor®, partially offset by net pricing pressures for Trulance® and certain non-promoted products. International Segment International segment reported revenues were $265 million for the first quarter of 2024, compared with $247 million for the first quarter of 2023, an increase of $18 million, or 7%. Introduction XIFAXAN (rifaximin) is an oral, non-absorbed antibiotic primarily prescribed for irritable bowel syndrome with diarrhea (IBS-D), hepatic encephalopathy (HE), and travelers' diarrhea. Since its approval, XIFAXAN has positioned itself as a critical therapeutic agent within the gastrointestinal pharmacology market. Analyzing its current market size, competitive positioning, and sales … Estimated Resupply Dates Bausch Health has Xifaxan 200 mg tablets on allocation. Please contact your wholesaler if you are having issues obtaining product. The guidance for 2025 is also encouraging. The Salix business maintained its momentum on the back of Xifaxan, which witnessed strong growth in underlying demand. Bausch Health's wholly-owned subsidiary, 1261229 B.C. LTD., entered into a financing commitment with a third-party lender to provide a senior secured credit facility of up to $700 million. Bausch Health Xifaxan: The US Supreme Court rejected Norwich Pharmaceuticals' attempt to sell a generic version of Bausch Health's diarrhea drug Xifaxan. The court upheld a lower court's ruling that found Norwich's generic would infringe on patents held by Bausch. Xifaxan generated over $1.8 billion in sales for Bausch in 2023. Bausch sued Norwich in 2020 over its intention to start selling a Xifaxan generic before the drug's patents expire. The US District Court of Delaware found last year that patents covering the composition and use of Xifaxan in irritable bowel syndrome with diarrhoea (IBS-D) were invalid, whereas it agreed that those covering the drug's use for … Conclusion: A Strategic Win for Bausch, a Long Game for Generics The ruling is a clear victory for Bausch Health, which can now project stable XIFAXAN® sales through 2028. With the drug's strong clinical profile and high patient demand, the extended exclusivity period provides a financial cushion as Bausch diversifies its portfolio. Introduction XIFAXAN (rifaximin) is an oral, non-absorbed antibiotic primarily prescribed for irritable bowel syndrome with diarrhea (IBS-D), hepatic encephalopathy (HE), and travelers' diarrhea. Since its approval, XIFAXAN has positioned itself as a critical therapeutic agent within the gastrointestinal pharmacology market. Analyzing its current market size, competitive positioning, and sales … Earlier this month, the new Valeant chief attributed Xifaxan's slump to "sales force disruption" over the past 12 months–something the company says it's been working to address by inserting … Now that Valeant's $10 billion talks to sell its Salix unit to Takeda have reportedly fallen through, the company is taking matters into its own hands with a "significant" GI sales force … Bausch Health and Teva Pharmaceuticals were sued on Monday for allegedly conspiring to delay sales of a generic version of Bausch's blockbuster diarrhea drug Xifaxan, causing buyers to pay … Although the FDA has granted tentative approval to Norwich Pharmaceuticals' 200 mg generic rifaximin, Bausch Health asserted in a company statement that full approval will not be given until … Salix Will Maintain Market Exclusivity for XIFAXAN®(rifaximin) 550 mg Tablets Until 20281 LAVAL, Quebec, May 6, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and … The drug is marketed by Bausch Health Companies Inc. In 2023, XIFAXAN generated approximately $584 million in net sales in the United States. This represents a 5% decrease compared to 2022 net sales of $615 million. [1] What are the Key Patent Expiries and Generic Landscape for XIFAXAN?
